InterveXion Announces Positive Data in Phase 2 Study of Devextinetug in Patients with METH Overdose
Devextinetug safe and well-tolerated in patients presenting with methamphetamine overdose, and normalized agitation without producing...
top of page
InterveXion Therapeutics, LLC
Search
intervexion
Jul 5, 20222 min read
InterveXion Enrolls First Patient in OUTLAST, a Phase 2 Study of IXT-m200 in METH Use Disorder
- First clinical trial of an anti-METH antibody in patients seeking treatment for methamphetamine use disorder LITTLE ROCK, ARKANSAS,...
intervexion
Apr 3, 20222 min read
InterveXion to Present Positive Phase 2 STAMPOUT Study Data at Upcoming CPDD Meeting
STAMPOUT is the first positive Phase 2 proof-of-concept trial for an anti-METH antibody LITTLE ROCK, ARKANSAS, USA, April 4, 2022...
bottom of page